Live feed07:00:00·36dPRReleasevia QuantisnowTozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPDByQuantisnow·Wall Street's wire, on your screen.AZN· AstraZeneca PLCHealth Care